Skip to content

CninMed – China Innovative Drugs Update

  • Contact Us

China Biotech M&A

Posted in
  • China Biotech M&A
  • China License Out

[China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)

Announced Date: 2024-11-13 (November 13, 2024) Licensor (Seller): Zhuhai Biotheus Inc (China) Licensee (Buyer): BioNTech . … [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)Read more

by admin•November 14, 2024September 18, 2025•1
Posted in
  • China Biotech M&A
  • China License Out

[China Biotech M&A] Genmab Completes Acquisition of ProfoundBio for USD 1.8 billion in cash, obtain ADC Portfolio and Platform

Announced Date: 2024-05-21 (May 21, 2024) Seller: ProfoundBio (China) Buyer:  Genmab A/S (Denmark) Payment: USD 1.8 … [China Biotech M&A] Genmab Completes Acquisition of ProfoundBio for USD 1.8 billion in cash, obtain ADC Portfolio and PlatformRead more

by admin•May 22, 2024September 18, 2025•0

Recent Posts

  • [China BD 2025] TransThera and Neurocrine Enters a 882 USD Million License on NLRP3 Inhibitor Program
  • China NMPA Approved New Drugs (Biological Products) ADC
  • [China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105
  • [China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031N
  • [China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on  Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)

Recent Comments

  1. [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327) – CninMed – China Innovative Drugs Update on [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  2. [Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products – CninMed – China Innovative Drugs Update on [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
  3. [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus) – CninMed – China Innovative Drugs Update on [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  4. admin on [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Categories

  • China Biotech M&A
  • China FIC Drug
  • China License Out
  • China New Drug
  • China NewCo
  • China Original Asset
  • China Tech Corp
Copyright © 2025 CninMed - China Innovative Drugs Update.
Powered by WordPress and HybridMag.
  • Contact Us